Company: IXHL
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001213900-25-013783
Chunk: 90

Company: Incannex Healthcare Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 8
Chunk 90
---
 as:

    ●
    the number and scope, rate of progress, expense and results of our clinical trials and preclinical studies, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities;

    ●
    per patient trial costs;

    ●
    the number of trials required for approval;

    ●
    the number of sites included in the trials;

19

    ●
    the countries in which the trials are conducted;

    ●
    the length of time required to enroll eligible patients;

    ●
    the number of patients that participate in the trials;

    ●
    the number of doses that patients receive;

    ●
    the drop-out or discontinuation rates of patients;

    ●
    the potential additional safety monitoring requested by regulatory agencies;

    ●
    the duration of patient participation in the trials and follow-up;

    ●
    the cost and timing of manufacturing of our drug candidates;

    ●
    the costs, if any, of obtaining third-party drugs for use in our combination trials;

    ●
    the extent of changes in government regulation and regulatory guidance;

    ●
    the efficacy and safety profile of our drug candidates;

    ●
    the timing, receipt, and terms of any approvals from applicable regulatory authorities; and

    ●
    the extent to which we establish additional collaboration, license, or other arrangements.

A change in the outcome of any of these variables
with respect to the development of our drug candidates could significantly change the costs and timing associated with the development
of that drug candidate. We may never succeed in obtaining regulatory approval for any drug candidate.

General and Administrative

General and administrative expenses consist primarily
of personnel-related expenses finance and accounting, human resources and other administrative functions, including salaries, stock-based
compensation and benefits for employees, legal fees, expenses relating to patent and corporate matters and professional fees paid for
accounting, auditing, consulting and tax services, as well as facilities-related costs not otherwise included in research and development
expenses and other costs such as insurance costs and travel expenses.

General and administrative expenses decreased by
$1.7 million for the three months ended December 31, 2024, compared to the three months ended December 31, 2023. The decrease was primarily
attributable to a decrease in employee benefits, resulting from a reduction in the amount of restricted stock issued to our directors
and officers.

General and administrative expenses decreased by
$0.3 million for